|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.8 USD | -6.74% |
|
+0.56% | -11.76% |
July 2 (Reuters) - Drug developer Semnur Pharmaceuticals said on Tuesday it has signed a letter of intent to go public through a merger with special purpose acquisition company Denali Capital Acquisition Corp in a pre-transaction equity deal valued at up to $2 billion.
Semnur is a unit of Scilex Holding. (Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 11.36 USD | +0.09% | -0.26% | 80.77M | ||
| 1.8 USD | -6.74% | +0.56% | 218M | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -11.76% | 218M | |
| +5.90% | 71.05B | |
| +22.38% | 9.03B | |
| -23.21% | 4.38B | |
| +16.13% | 4.27B | |
| +19.42% | 3.73B | |
| 0.00% | 1.99B | |
| +6.54% | 1.96B | |
| -39.09% | 1.87B | |
| -46.93% | 1.71B |
SCILEX HOLDING COMPANY 
